{
    "id": 2751,
    "fullName": "PML - RARA",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "PML-RARA results from the fusion of PML and RARA, which leads to enhanced dimerization, increased transcriptional repression, transformation in cell culture and pathogenesis of acute promyelocytic leukemia in animal models (PMID: 25119106).",
            "references": [
                {
                    "id": 1345,
                    "pubMedId": 25119106,
                    "title": "The DNA binding property of PML/RARA but not the integrity of PML nuclear bodies is indispensable for leukemic transformation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25119106"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5371,
        "geneSymbol": "PML",
        "terms": [
            "PML",
            "MYL",
            "PP8675",
            "RNF71",
            "TRIM19"
        ]
    },
    "variant": "PML - RARA",
    "createDate": "12/17/2014",
    "updateDate": "08/31/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 5914,
                "geneSymbol": "RARA",
                "terms": [
                    "RARA",
                    "NR1B1",
                    "RAR"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 4389,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In clinical studies that supported FDA approval, treatment with Tretinoin in acute promyelocytic leukemia patients harboring PML-RARA induced remission and resulted in improved survival when compared to chemotherapeutics (PMID: 8291820, PMID: 8712802, PMID: 1850498).",
            "molecularProfile": {
                "id": 2571,
                "profileName": "PML - RARA"
            },
            "therapy": {
                "id": 1877,
                "therapyName": "Tretinoin",
                "synonyms": null
            },
            "indication": {
                "id": 60318,
                "name": "acute promyelocytic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4511,
                    "pubMedId": 8291820,
                    "title": "All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/8291820"
                },
                {
                    "id": 4512,
                    "pubMedId": 1850498,
                    "title": "Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/1850498"
                },
                {
                    "id": 10792,
                    "pubMedId": 8712802,
                    "title": "Pathogenesis and management of acute promyelocytic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/8712802"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4722,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical trial that supported FDA approval, treatment with Trisenox (arsenic trioxide) resulted in complete remission in 85% (34/40) of acute promyelocytic leukemia patients harboring PML-RARA, with conversion to no detectable PML-RARA fusion in 86% of patients assessed by RT-PCR (PMID: 11559723).",
            "molecularProfile": {
                "id": 2571,
                "profileName": "PML - RARA"
            },
            "therapy": {
                "id": 640,
                "therapyName": "Arsenic trioxide",
                "synonyms": null
            },
            "indication": {
                "id": 60318,
                "name": "acute promyelocytic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10759,
                    "pubMedId": 11559723,
                    "title": "United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/11559723"
                },
                {
                    "id": 15572,
                    "pubMedId": null,
                    "title": "Trisenox (arsenic trioxide) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021248"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 5515,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In clinical case study, a patient with acute promyelocytic leukemia harboring PML-RARA treated with arsenic trioxide initially demonstrated a response, but subsequently developed resistance due to a secondary mutation, PML L218P (PMID: 21613260).",
            "molecularProfile": {
                "id": 20956,
                "profileName": "PML - RARA PML L218P"
            },
            "therapy": {
                "id": 640,
                "therapyName": "Arsenic trioxide",
                "synonyms": null
            },
            "indication": {
                "id": 60318,
                "name": "acute promyelocytic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 5077,
                    "pubMedId": 21613260,
                    "title": "Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21613260"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5516,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with acute promyelocytic leukemia harboring PML-RARA treated with arsenic trioxide initially demonstrated a response, but subsequently developed resistance due to a secondary mutation, PML A216V (PMID: 21613260).",
            "molecularProfile": {
                "id": 20957,
                "profileName": "PML - RARA PML A216V"
            },
            "therapy": {
                "id": 640,
                "therapyName": "Arsenic trioxide",
                "synonyms": null
            },
            "indication": {
                "id": 60318,
                "name": "acute promyelocytic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 5077,
                    "pubMedId": 21613260,
                    "title": "Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21613260"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2571,
            "profileName": "PML - RARA",
            "profileTreatmentApproaches": [
                {
                    "id": 7615,
                    "name": "Tretinoin",
                    "profileName": "PML - RARA"
                },
                {
                    "id": 7614,
                    "name": "Arsenic trioxide",
                    "profileName": "PML - RARA"
                }
            ]
        },
        {
            "id": 20956,
            "profileName": "PML - RARA PML L218P",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20957,
            "profileName": "PML - RARA PML A216V",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}